A number of hair loss company news updates came in all at once this week. Thanks to the readers who posted several of the below links.
Stemson Targets UK
In September, I updated my last post on Stemson Therapeutics after they garnered new investment of $7.5 million from UK-based Fortunis Capital.
“The announcement of the $7.5million seed funding last month has triggered significant interest from UK government agencies as well as generated thousands of inquiries from people who wish to take part in the first tests.”
Histogen on Track
Considering Histogen’s past ups and downs, I cannot say that they are “on track” while keeping a straight face. In any case, this second time around, they do seem to have a better leadership team.
Yesterday, Histogen announced that in October they completed their hair loss product HST-001 dosing for week 12. This is the last of three dosing timepoints in the product’s Phase 1b/2a clinical trials. They remain on track to announce top-line results in the fourth quarter of 2020. More here.
Replicel (Canada) always seems to manage to get just enough funding to stay alive every year. Yesterday, they garnered CAD $2.7 million from MainPointe Pharmaceuticals (US). The two companies also entered into a strategic partnership. Subsequently, Replicel’s always volatile stock price went up by 50 percent in one day. And another 12 percent so far today.
More relevant is this Tweet from the company earlier today regarding their aim to resolve partnership issues with Shiseido. As far as I know, Replicel has not released any products since it was incepted in 2010. However, their dermal injector device is close to release per the pipeline.